Form D · Biotechnology
Caspian Therapeutics, Inc.
San Diego, CA · CIK 0002156247
Offering snapshot reported Sep 23, 2026 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 43 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 8, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Initial | $50,000,000 | No comparison | 43 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598559
Source: Form D, filed Sep 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Spike Loy | Director |
| Robert H. Spencer | Executive |
| Troy E. Wilson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4930 Directors Place
San Diego, CA, 92121
Phone: (858) 500-8800
San Diego, CA, 92121
Phone: (858) 500-8800